本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

ALX Oncology Holdings

1.58
+0.200014.49%
成交量:19.61万
成交额:30.06万
市值:8,566.44万
市盈率:-0.78
高:1.61
开:1.39
低:1.38
收:1.38
52周最高:2.27
52周最低:0.4040
股本:5,421.80万
流通股本:2,899.09万
量比:3.63
换手率:0.68%
股息:- -
股息率:- -
每股收益(TTM):-2.0202
每股收益(LYR):-2.5846
净资产收益率:-104.21%
总资产收益率:-47.78%
市净率:1.33
市盈率(LYR):-0.61

数据加载中...

公司资料

公司名字:
ALX Oncology Holdings
交易所:
NASDAQ
成立时间:
2015
员工人数:
44
公司地址:
323 Allerton Avenue,South San Francisco,California,United States
邮编:
94080
电话:
传真:
- -
简介:
ALX Oncology Holdings Inc.于2020年4月1日成立。该公司是一家临床阶段的免疫肿瘤学公司,专注于通过开发阻断CD47免疫检查点和连接先天和适应性免疫系统的疗法来帮助患者对抗癌症。

董事

名称
职位
Corey Goodman
Executive Chairman of the Board
Jason Lettmann
Chief Executive Officer and Director
Alan B. Sandler
Director and Chief Medical Officer
Chris H. Takimoto
Independent Director
Rekha Hemrajani
Independent Director
Scott Garland
Independent Director
Daniel Curran
Director

股东

名称
职位
Jason Lettmann
Chief Executive Officer and Director
Harish Shantharam
Chief Financial Officer
Shelly Pinto
Senior Vice President, Finance and Chief Accounting Officer
Alan B. Sandler
Director and Chief Medical Officer
Corey Goodman
Executive Chairman of the Board